Esperion Therapeutics (NASDAQ:ESPR) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus set a $105.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 7th. UBS set a $88.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective on the stock in a research report on Friday, January 5th. Deutsche Bank increased their price objective on Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. Finally, ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $90.62.

How to Become a New Pot Stock Millionaire

Esperion Therapeutics (NASDAQ ESPR) opened at $75.32 on Tuesday. The firm has a market capitalization of $1,961.21, a price-to-earnings ratio of -10.73 and a beta of 2.45. Esperion Therapeutics has a 12-month low of $30.95 and a 12-month high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.36. During the same period in the prior year, the firm posted ($1.29) EPS. equities analysts expect that Esperion Therapeutics will post -5.66 earnings per share for the current year.

In other news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now directly owns 3,177 shares of the company’s stock, valued at approximately $228,076.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 32.50% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. acquired a new stake in Esperion Therapeutics in the fourth quarter valued at about $222,000. BB&T Securities LLC acquired a new stake in Esperion Therapeutics in the fourth quarter valued at about $263,000. First Mercantile Trust Co. boosted its stake in Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,519 shares in the last quarter. Creative Planning acquired a new stake in Esperion Therapeutics in the fourth quarter valued at about $314,000. Finally, Oakmont Partners LLC acquired a new stake in Esperion Therapeutics in the fourth quarter valued at about $323,000. 91.66% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Esperion Therapeutics (ESPR) Rating Lowered to Hold at BidaskClub” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/esperion-therapeutics-espr-rating-lowered-to-hold-at-bidaskclub/1956305.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.